Related by context. All words. (Click for frequent words.) 71 Azedra 67 Traficet EN 67 Sym# 67 PSMA ADC 67 metaglidasen 66 TG# [003] 66 OncoVEX GM CSF 66 AQ4N 66 cannabinor 66 AeroLEF TM 66 liposomal formulation 66 Proxinium TM 65 AEG# 65 ACAPODENE 65 VA# [002] 65 teriflunomide 65 IRX 2 65 Amrubicin 65 ATL# [002] 65 EOquin 65 CCX# 65 Neuradiab 65 Phase IIa trials 65 PORxin TM 65 MGd 65 INT# [002] 65 HQK 64 IMA# 64 RLY# 64 busulfan 64 Panzem R NCD 64 R#/MEM # 64 MEK inhibitor 64 Chrysalin 64 REG1 64 Bezielle 64 Archexin 64 RhuDex ® 64 phase IIa clinical 64 Degarelix 64 JAK inhibitor 64 CIMZIA ™ 64 HGS ETR1 64 PDE4 inhibitor 64 PRT# 64 Capesaris 64 selective androgen receptor modulator 64 PEG SN# 64 Guanilib 64 ATL# [001] 64 oral prodrug 64 vidofludimus 64 EndoTAG TM -1 64 dose limiting toxicities 63 targeted radiotherapeutic 63 XmAb# 63 Amplimexon 63 Trofex 63 Myocet 63 Symadex 63 CEQ# 63 Androxal TM 63 OHR/AVR# 63 CA4P 63 Chemophase 63 Pimavanserin 63 Spheramine 63 indibulin 63 Nanobody 63 Trastuzumab 63 elotuzumab 63 NP2 Enkephalin 63 opioid induced bowel dysfunction 63 Phase #b/#a trial 63 favorable pharmacokinetic profile 63 EOquin TM 63 HuMax EGFr 63 CBLC# 63 CB2 selective receptor agonist 63 ESBA# 63 luteinizing hormone releasing 63 PROCHYMAL 63 Bendavia 63 triphendiol 63 volociximab 63 MYDICAR ® 63 alagebrium 63 preclinically 63 preclinical efficacy 63 trial evaluating PRX# 63 TH# [003] 63 Elocalcitol 63 JAK inhibitors 62 LHRH agonists 62 Vicinium TM 62 DACH platinum 62 depsipeptide 62 ENMD # 62 Durezol 62 systemically administered 62 ostarine 62 Ostabolin C 62 BiTE 62 Phase 2a trial 62 davunetide intranasal AL 62 mertansine 62 cilengitide 62 5 HT2C receptor 62 Factor VIIa 62 dose escalation Phase 62 nalbuphine ER 62 DOS# 62 Sapacitabine 62 MAGE A3 ASCI 62 elacytarabine 62 GLP toxicology studies 62 huC# DM4 62 Tamibarotene 62 Azedra TM 62 PSN# [001] 62 nanopharmaceutical 62 radiation sensitizer 62 uricase 62 LEUKINE 62 Ophena TM 62 BrachySil TM 62 Nanobody ® 62 BiTE antibody 62 VAPRISOL 62 Blinatumomab 62 Pradefovir 62 GED aPC 62 obatoclax 62 iSONEP 62 phase IIb study 62 PREOS R 62 Alocrest 62 RAPAFLO 62 Octreotide 62 phase IIb clinical 62 plasma kallikrein inhibitor 62 Novolimus 62 ANG# 62 Aplidin 62 methylnaltrexone 62 TBC# 62 goserelin 62 ABSORB trial 62 pharmacodynamic effects 61 Zoraxel 61 Zyclara 61 ularitide 61 BRIM2 61 CYT# potent vascular disrupting 61 Bicifadine 61 romidepsin 61 anticancer agent 61 Onalta 61 Phase IIB 61 Imprime PGG 61 OXi# 61 proteasome inhibitor 61 Aloxi injection 61 PhG alpha 1 61 Xanafide 61 amrubicin 61 Aflibercept 61 Lixivaptan 61 CR# vcMMAE 61 PF # [001] 61 evaluating tivozanib 61 XIENCE V stent 61 CCR9 antagonist 61 Phase Ib clinical 61 corticosteroid dexamethasone 61 Alzhemed TM 61 orally bioavailable 61 superficial bladder cancer 61 ApoB SNALP 61 Atu# 61 Phase #b/#a 61 Squalamine 61 generation FBPase inhibitor 61 Phase Ib study 61 pradefovir 61 PLK1 SNALP 61 OMP #M# 61 OMS# 61 QT QTc 61 Fibrillex TM 61 OvaRex ® MAb 61 rxRNA 61 Pertuzumab 61 PXD# 61 PEGylated interferon 61 CRLX# 61 BrachySil 61 SPC# [001] 61 atacicept 61 siRNA therapeutic 61 FK# 61 HGS ETR2 61 Annexin V 61 INCB# [001] 61 CD# monoclonal antibody 61 investigational humanized monoclonal antibody 61 Glypromate 61 DXL# 61 Pemetrexed 61 ThermoDox R 61 humanized antibody 61 zotarolimus 61 SLx 61 ALB # 61 biologic therapy 61 Phase 2b clinical trials 61 hormone LHRH antagonist 61 PD LID 61 GSK# [001] 61 orally dosed 61 CTAP# Capsules 61 mGluR2 NAM 61 teduglutide 61 topical formulation 61 ZFP TF 61 PS# [001] 61 Ophena 61 fosbretabulin 61 Marqibo TM 61 Doxorubicin 61 dextofisopam 61 relapsed multiple myeloma 60 glufosfamide 60 ulimorelin 60 Phase 1b 60 CINTREDEKIN BESUDOTOX 60 IMC A# 60 noninfectious uveitis 60 deforolimus 60 PEGPH# 60 SNT MC# 60 CORT # 60 TriRima 60 HGS# 60 Exherin TM 60 CG# [003] 60 decitabine 60 Phase 2a clinical 60 Seliciclib 60 GAMMAGARD 60 urethral bulking agent 60 Phase 1b clinical trials 60 Apoptone 60 Annamycin 60 ozarelix 60 pharmacokinetic PK study 60 Phase 1a clinical 60 PSN# [002] 60 MoxDuo ® IR 60 ATL/TV# 60 SERMs 60 MAXY G# 60 eniluracil 60 NLX P# 60 NU# [001] 60 luliconazole 60 CIMZIA TM 60 EXPAREL 60 forodesine 60 Oral NKTR 60 hematological tumors 60 cobiprostone 60 ARIKACE 60 ProSavin 60 CD# antibody [001] 60 lomitapide 60 synthetic retinoid 60 C1 INH 60 thymalfasin 60 NTDDS 60 Phase IIb clinical trials 60 Phase 2b study 60 EDEMA3 60 Mipomersen 60 Cannabinor 60 refractory prostate cancer 60 oncolytic vaccine 60 Etoposide 60 Adlea 60 RAV# 60 ospemifene 60 DB# [003] 60 Phase 2a clinical trials 60 alvespimycin 60 LT NS# 60 pomalidomide 60 MEK inhibitors 60 ANAVEX #-# [001] 60 visilizumab 60 immunomodulatory therapy 60 ONTAK 60 pharmacokinetic characteristics 60 pertuzumab 60 FVIIa 60 Troxatyl 60 bevacizumab Avastin ® 60 octreotide 60 IFN α 60 ONX 60 Liposomal 60 ALN TTR# 60 rhMBL 60 HuLuc# 60 RECOTHROM R 60 rhIL 7 60 DepoDur TM 60 Prodarsan ® 60 Solazed 60 miglustat 60 mGluR5 NAM 60 HspE7 60 BNC# 60 sulodexide 60 TELINTRA 60 APTIVUS r 60 Thorough QT 60 ELACYT 60 ALN VSP 60 tesmilifene 60 Ocrelizumab 60 preclinical toxicology 60 granisetron 60 Triolex 60 omega interferon 60 TRC# 60 humanized anti 60 KNS # 60 DermaPrep 60 Carfilzomib 60 Ostarine 60 Panzem 60 gonadotropin releasing hormone GnRH 60 anti EGFR antibody 60 Phase 2a 60 Combo Stent 60 PGL# 60 MAP# 60 BEMA TM Fentanyl 60 YONDELIS 60 HSP# inhibitor 60 Tyrima 60 VitiGam 60 alefacept 60 pharmacological chaperone 60 vivo potency 60 Ozarelix 60 Urocidin 59 novel histone deacetylase 59 KSP inhibitor 59 malignant ascites 59 Dasatinib 59 tezampanel 59 TACI Ig 59 prodrug 59 Apaziquone 59 administered subcutaneously 59 EXPAREL TM 59 pegylated liposomal doxorubicin 59 GRN# 59 analgesic efficacy 59 rFIXFc 59 pharmacokinetic PK 59 blinatumomab 59 Anticalin R 59 Omacetaxine 59 trospium 59 Aurexis 59 mecamylamine 59 ALN TTR 59 Ramoplanin 59 anti leukemic 59 Enzyme Replacement Therapy 59 Phase Ib clinical trials 59 humanized monoclonal antibody 59 ocular formulation 59 ZOLINZA 59 ALGRX 59 Maribavir 59 GRNVAC1 59 concurrent chemoradiation 59 Vidofludimus 59 Safinamide 59 Daclizumab 59 CDK inhibitor 59 Phase #b/#a clinical 59 ISF# 59 PNP inhibitor 59 plasma pharmacokinetics 59 rBChE 59 Gefitinib 59 ARIKACE ™ 59 prostone 59 Beta catenin pathway 59 P#X# 59 SAR# [002] 59 imetelstat 59 Vascugel 59 UVIDEM 59 Synavive 59 Cethrin 59 benign prostatic hyperplasia enlarged 59 urocortin 2 59 Sudhir Agrawal D.Phil 59 Posiphen 59 azacytidine 59 pan HDAC inhibitor 59 TAFA# 59 NOD SCID mice 59 Anavex #-# 59 nucleotide analog 59 GV# [001] 59 riociguat 59 brivaracetam 59 Phase Ib II 59 HCD# [002] 59 Gastrointestinal Stromal Tumors 59 Cardio Vascu Grow 59 Vilazodone 59 alvimopan 59 Tarvacin TM 59 anticancer activity 59 acetonide FA 59 TMS Therapy 59 SUTENT ® 59 Cotara 59 Plenaxis TM 59 CTCE 59 oral antiviral 59 targeting CD# 59 Onconase 59 rilonacept 59 eosinophilic asthma 59 Toxicities 59 angiogenesis inhibitor 59 flavopiridol 59 Glufosfamide 59 EVIZON 59 CIPN 59 liposomal doxorubicin 59 beta 1a 59 Elitek 59 IAP inhibitor 59 IMC #B 59 Nasulin 59 pharmacodynamic PD 59 TRX# 59 antiangiogenic therapy 59 RSD# oral 59 AMD# [003] 59 Irinotecan 59 CD# CEA 59 CERE 59 ACZ# 59 Aurora Kinase 59 XL# XL# 59 KRN# 59 GORE TAG Device 59 LHRH antagonists 59 rindopepimut 59 sipuleucel T 59 subcutaneous formulation 59 MGCD# [001] 59 anticancer compound 59 bicalutamide 59 Cethrin R 59 Dacogen injection 59 pitavastatin 59 mapatumumab 59 PRLX # 59 ZYBRESTAT fosbretabulin 59 SCCHN 59 Amigal 59 NEUMUNE 59 Gabapentin GR 59 Pharmacokinetic studies 59 tafamidis 59 Dr. Fahar Merchant 59 EDEMA3 trial 59 elagolix 59 DP b# 59 Voreloxin 59 ThGRF 59 humanized monoclonal 59 GEM OS2 59 solithromycin 59 erythropoietic 59 Onco TCS 59 Critical Limb Ischemia CLI 59 SPIRIVA HandiHaler 59 chemotherapeutic drug 59 vinca alkaloid 59 Phase IIa trial 59 TG# [001] 59 DDP# 59 relapsed MM 59 QuadraSphere 59 nonclinical studies 59 antitumor effects 59 Interferon alpha 59 TARIS 59 Stedivaze 59 Protexia R 59 tosedostat 59 compound AEOL # 59 TNF Tumor Necrosis Factor 59 immunotherapeutic agent 59 APTIVUS 59 tumor xenograft models 59 Viprinex TM 59 PNT# 59 mAb 59 MNTX 59 NTx TM -# 59 PKC# 59 Epratuzumab 59 TRO# 59 PARP inhibitor 59 Cloretazine R VNP#M 59 #beta estradiol 59 PORxin 59 vismodegib 59 APOPTONE 59 INxin 59 JAK3 59 Quinamed 59 VBLOC Therapy 59 TPI ASM8 59 TriGrid ™ 59 Zybrestat 59 MDV# 59 XL# [003] 59 histone deacetylase HDAC inhibitor 59 CardioPET 59 ZK EPO 59 generation antisense 59 huN# DM1 59 ZACTIMA 59 INC# 59 Lubiprostone 59 Alfimeprase 59 Excellarate 59 Bevasiranib 59 tramiprosate 59 ablative therapy 59 Alpharadin 59 Neurodex 59 LHRH antagonist 59 ISTODAX 59 treat benign prostatic 58 veltuzumab 58 NEBIDO 58 GSK# [002] 58 gemcitabine cisplatin 58 bardoxolone methyl 58 protein kinase inhibitor 58 cytostatic 58 ISIS # 58 Relivar 58 oncolytic 58 intratumoral injection 58 Litx 58 CCX# B 58 M6G 58 TASQ 58 TIMP 1 58 SinuNase ™ 58 Spiegelmer ® 58 zileuton 58 PI3K/mTOR 58 oral ridaforolimus 58 DAVANAT 58 GLP1 agonist 58 acute GvHD 58 enzastaurin 58 rHuPH# 58 ThermoDox ® 58 Rasagiline 58 Dapagliflozin 58 parathyroid hormone PTH 58 Actilon 58 statistically significant efficacy 58 Virulizin ® 58 Valdoxan 58 GFT# 58 Phase 2b trial 58 pharmacodynamic profile 58 PEGylated 58 CANCIDAS 58 ART# 58 CTA# 58 ORENCIA R 58 mu opioid receptor antagonist 58 Phase #/#a 58 therapeutic monoclonal antibody 58 drug eluting stent DES 58 custirsen 58 nonsmall cell lung cancer 58 JAK1 58 HuMax CD# 58 FOLFOX6 58 Resten NG 58 Aeroquin 58 MEK inhibitor RDEA# 58 HER2 positive metastatic breast 58 Atiprimod 58 SinuNase TM 58 Darusentan 58 Lu AA# 58 NOX E# 58 IgG1 antibody 58 effector function 58 PREOS 58 vascular disrupting agents 58 Zemiva 58 SCIg 58 dacetuzumab 58 PEGylated Fab fragment 58 cortical stimulation 58 BZL# 58 octreotide implant 58 CYC# 58 Trofex TM 58 oral talactoferrin 58 GRN#L 58 pharmacodynamic properties 58 Enkephalin 58 proteasome inhibitors 58 GRASPA ® 58 eculizumab 58 ON #.Na 58 demonstrated antitumor activity 58 ONCONASE 58 Luteinizing Hormone Releasing Hormone 58 cMET 58 Elagolix 58 BMS# 58 Temsirolimus 58 cancer immunotherapies 58 CBLB# 58 drug conjugate 58 midstage trials 58 dosage regimens 58 IV Busulfex 58 Zerenex 58 ibandronate 58 Meets Primary Endpoint 58 PS# DARA 58 Phase III Pivotal 58 CXB# 58 Insegia 58 Aurora kinase 58 ZD# [001] 58 canakinumab 58 Androxal ® 58 phase IIb trial 58 Kahalalide F 58 lumiliximab 58 EZN 58 Solazed TM 58 RDEA# 58 PDE4 inhibitors 58 XOMA 3AB 58 LHRH agonist 58 HDAC Inhibitor 58 BENICAR HCT 58 anti fibrotic 58 rNAPc2 58 MBP# [001] 58 OncoVEX 58 budesonide foam 58 cetrorelix 58 ELND# 58 IMP# 58 GLYX 58 partial agonist 58 novel peptide 58 lenalidomide Revlimid R 58 Soliris eculizumab 58 Harbor BioSciences 58 Viprinex 58 HuMax CD4 58 DEB# 58 Phase IIIb clinical 58 Radilex 58 5 HT6 receptor 58 CIMZIA TM certolizumab pegol 58 alpha#beta# integrin 58 non nucleoside 58 ASONEP 58 Tarvacin 58 talabostat 58 GLPG# 58 Locteron 58 trodusquemine 58 subcutaneously administered 58 Pharmacokinetics PK 58 Phase IIa clinical 58 Emselex 58 TOCOSOL Paclitaxel 58 AP# [003] 58 ALN PCS 58 CaPre TM 58 Telatinib 58 tubulin inhibitor 58 Cleviprex TM clevidipine 58 bicifadine 58 somatostatin analogue 58 EP #R 58 #I TM# 58 BAL# [002] 58 Romidepsin 58 zalutumumab 58 vorinostat 58 HCV NS5B polymerase 58 ACV1 58 S/GSK# 58 refractory angina 58 Aerosurf 58 CoFactor 58 Microplasmin 58 aerosolized KL4 surfactant 58 Aliskiren 58 NXL# 58 AXIRON ™ 58 tanespimycin 58 sitaxsentan 58 cartilage regeneration 58 L PPDS 58 vascular disrupting 58 TKM ApoB 58 Cx# [002] 58 MoxDuo 58 Q#IR 58 THR beta agonist 58 CHARISMA trial 58 antitumor activity 58 BRAF inhibitor 58 Chemokine 58 Raptiva ® 58 trastuzumab emtansine T DM1 58 leading oral taxane 58 ONCONASE R 58 castrate resistant prostate cancer 58 axitinib 58 ORENCIA ® 58 Serdaxin 58 PRTX 58 Phase IIa clinical trials 58 Fortical R 58 refractory gout 58 lipid nanoparticle LNP 58 INCB# [002] 58 intranasal formulation 58 Menerba 58 sunitinib malate 58 recurrent NSCLC 58 ganetespib 58 E1 INT TM 58 lenalidomide dexamethasone 58 histone deacetylase inhibitor 58 Hepatocellular Carcinoma HCC 58 Plicera 58 TRV# [001] 58 PCK# 58 immunomodulator 58 Arikace 58 ARCALYST ® 58 MT# MEDI 58 selective modulator 58 farletuzumab 58 SPIRIVA ® 58 Zysolin TM 58 intravesical instillation 58 castration resistant prostate cancer 58 HuMax 58 CYT# 58 intravesical 58 PLX cells 58 dose cohort 58 Debio 58 #ME# 58 CINQUIL 58 Phase III Clinical Trial 58 palifosfamide 58 omecamtiv mecarbil 58 Perifosine 58 Dacogen decitabine 58 oral tyrosine kinase 58 paclitaxel eluting stent 58 Locked Nucleic Acid LNA 58 topically administered 58 myelofibrosis polycythemia vera 58 placebo controlled clinical 58 diarrhea predominant irritable 57 Bortezomib 57 Aptivus ® 57 Biomerk Tumorgrafts 57 HDACi 57 Simulect 57 thalidomide Thalomid 57 GHRH 57 Vascugel R 57 rALLy clinical trial 57 bortezomib Velcade 57 TKB# 57 6R BH4 57 epothilone 57 Ataluren 57 INTERCEPT platelets 57 proteasome inhibitor bortezomib 57 sd rxRNA 57 afamelanotide 57 HGS ETR1 mapatumumab 57 tecarfarin 57 eprotirome 57 Phase 1b clinical 57 carcinoid syndrome 57 efficacy endpoint 57 Phase #/#a trial 57 OMP #R# 57 MGN# 57 Gleevec resistant 57 antisense drug 57 TELCYTA 57 Loramyc R 57 DU #b 57 Tolvaptan 57 multicenter Phase II 57 ChronVac C ® 57 CRD5 57 AzaSite Plus 57 docetaxel Taxotere ® 57 MoxDuo TM IR 57 velafermin 57 Vorinostat 57 AeroLEF 57 PEP# [003] 57 oral deforolimus 57 Nanobodies ® 57 alpha blocker 57 AMPK activators 57 dosing cohort 57 tgAAC# 57 Reolysin 57 Thiarabine 57 Benign Prostatic Hyperplasia 57 PDE# inhibitors 57 antitumor 57 Ampligen ® 57 Frova ® 57 NGX# 57 ProLindac TM 57 lintuzumab 57 apremilast 57 antibody MAb 57 Revimmune 57 peptide conjugated 57 Nimotuzumab 57 Altastaph 57 XP #L 57 ancrod 57 Fx #A 57 gefitinib Iressa 57 Fulvestrant 57 inotropic 57 lanthanum carbonate 57 taxane derivative 57 INCB# [003] 57 CGEN # 57 metastatic neuroendocrine tumors 57 Allovectin 7 57 DermaVir Patch 57 samalizumab 57 confirmatory Phase III 57 Fc fusion protein 57 IAP inhibitors 57 DuraSite 57 Zemplar Capsules 57 IND submission 57 GALNS 57 Vaprisol 57 DAPT 57 AZX# 57 uric acid lowering 57 selective agonist 57 recurrent glioblastoma multiforme 57 NPC 1C 57 Antiviral Activity 57 Lisofylline LSF 57 cabozantinib 57 calcitonin 57 micafungin 57 Pathway Inhibitor 57 relapsing multiple sclerosis 57 Gemcitabine 57 Androxal 57 Fentanyl TAIFUN R 57 polymerase inhibitor 57 Hsp# Inhibitor 57 Dyloject TM 57 tumor necrosis 57 cediranib 57 somatostatin analog 57 Janus Kinase 57 Isolagen Process 57 HCV protease inhibitors 57 Phase III Clinical Trials 57 tolerability profiles 57 vascular disrupting agent 57 ganaxolone 57 Survivin antagonist 57 GVAX 57 Phase IIb clinical 57 GnRH antagonist 57 Iloperidone 57 metastatic malignant 57 abiraterone acetate 57 paclitaxel poliglumex 57 P#X# antagonist 57 Angiocept 57 OvaRex MAb 57 Cloretazine 57 HCV protease inhibitor 57 PTH analogue 57 seliciclib 57 LB# [003] 57 CCR5 antagonist 57 CRMD# 57 QTinno TM 57 FXIII 57 Ofatumumab 57 NSCLC tumors 57 alkylating agent 57 docetaxel Taxotere R 57 EndoTAG TM 57 isavuconazole 57 TOCOSOL Camptothecin 57 sorafenib Nexavar ® 57 Nanobodies 57 chemotherapy induced neutropenia 57 prostate cancer CRPC 57 trastuzumab DM1 T DM1 57 postsurgical pain 57 tivozanib 57 LHRH receptor positive 57 OMNARIS Nasal Spray 57 PORxin TM platforms 57 Panzem R 57 BrachySil ™ 57 receptor tyrosine kinase inhibitor 57 resolvin 57 systemic RNAi therapeutic 57 TLK# 57 delafloxacin 57 octreotide LAR 57 Proquin XR 57 investigational monoclonal antibody 57 Zenvia Phase III 57 novel oral anticoagulant 57 AKT inhibitor 57 pegylated interferons 57 R#/MEM 57 antitumor effect 57 Protelos 57 Asentar 57 varespladib 57 SparVax ™ 57 angiographic outcomes 57 radiolabeled 57 nicotinic alpha 7 57 TEMSO 57 M1 muscarinic 57 AAG geldanamycin analog 57 JVRS 57 sumatriptan DosePro 57 antimitotic 57 Indaflex TM 57 omacetaxine mepesuccinate 57 aflibercept VEGF Trap 57 PrevOnco ™ 57 menadione 57 bendamustine 57 MEND CABG 57 erlotinib Tarceva ® 57 Curaxin 57 pharmacokinetic equivalence 57 Valortim R 57 BAY #-# 57 #D#C#